Collectively, these studies suggest that ELR+CXC chemokines and their receptors, axis may play an important role in neutrophil recruitment and mediate early allograft injury, which is a known risk factor for the pathogenesis and development of chronic liver allograft dysfunction

Collectively, these studies suggest that ELR+CXC chemokines and their receptors, axis may play an important role in neutrophil recruitment and mediate early allograft injury, which is a known risk factor for the pathogenesis and development of chronic liver allograft dysfunction. ELRCXC chemokines include CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, and CXCL14. patients who survive longer than 5 years shows that 37% of recipients present with chronic liver allograft dysfunction [2]. The pathological hallmarks of end stage chronic liver allograft dysfunction include hepatocyte necrosis, hepatic arterial proliferative occlusive disease, bile duct disappearance, and eventually liver fibrosis [3]. That pathological changes usually precede functional deterioration in cases of chronic liver allograft dysfunction is characterized [3]. Treatment LY3009120 options in patients with advanced chronic liver allograft dysfunction are limited because of the diffuse nature of the disease. The currently available drug treatments are ineffective. Additionally, retransplantation Rabbit Polyclonal to Gastrin has limited applicability and success because of donor availability. Hence, chronic liver allograft dysfunction still is a common and frequently fatal, yet poorly treatable, complication of liver transplantation. Although the pathogenesis of chronic liver allograft dysfunction is not completely defined, it is believed that the histopathologic changes in this LY3009120 patient population can be attributed to early allograft dysfunction [4], acute or chronic rejection [5,6], de novo or recurrent autoimmune disease [7], de novo or recurrent viral hepatitis [3], drugs toxicity [8,9], late effects of ischemia/reperfusion (I/R) injury [10] or ischemic-type biliary lesions [11,12], and other recurrent diseases [13]. Causes of chronic liver allograft dysfunction are variable and are shown inTable 1. The molecular mechanisms of chronic liver allograft dysfunction are still unclear. Several reports have shown that chronic liver allograft dysfunction is caused by repeated episodes of chemotactic mediated injury to the liver graft [14,15]. And these forms of injury are inflicted on the allograft throughout all stages of transplantation [16]. == Table 1. == Causes of chronic liver allograft dysfunction. HBV: hepatitis B virus; HCV: hepatitis C virus; I/R injury: ischemia reperfusion injury; PSC: primary sclerosing cholangitis; PBC: primary biliary cirrhosis. Chemokines are a group of low-molecular-weight (8 to 14 kDa) [17] cytokines of which their common properties are to induce inflammatory cells migration and regulate inflammatory responses. However, recent studies show that chemokines impinge on many facets of biology including angiogenesis, haematopoiesis, mitogenesis, tumour growth and metastasis [14,18], and participating in the development of the immune system and in innate and acquired immune responses [19,20]. Dysregulated expression of chemokines and their receptors is involved in the pathogenesis of many human diseases including chronic inflammatory diseases, autoimmune diseases, immunodeficiency, and cancer. Furthermore, chemokines are essential mediators for attracting immune cells and for activating nonparenchymal liver cells [21]. And there is also emerging evidence that these chemokines and their receptors are linked with chronic liver allograft dysfunction development in animal studies [16]. For their involvement in a number of pathological processes, chemokines and their receptors represent important pharmaceutical targets for many diseases [65]. In addition, genetically recombinated/engineered small-molecule chemokine or chemokine inhibitors are emerging in reports both in the literature and at international conferences. In this review we will outline the recent progress in chemokines research with regard to the pathogenesis and development of chronic allograft dysfunction after liver transplantation. Each class of chemokines is discussed separately in this paper. == 2. Chemokine Superfamily == Since the first member of chemokines/cytokines, platelet factor 4 (PF-4/CXCL4), being discovered in 1955 [66], the family members of chemokines are more than 50 now. Because these molecules are closely related in structure and function, enormous chemokines and chemokine receptors were newly discovered in recent years. According to the presence of a conserved cysteine residue at the NH2terminus [67], the chemokine superfamily is divided into four subfamilies: C, CC, CXC, and CX3C. The first and third cysteines are missing in the C subfamily, while these two cysteines are adjacent in CC chemokines. In the CXC subfamily, one amino acid separates LY3009120 the first two cysteines, while in CX3C chemokines, three amino acids between the two cysteines. Based on the presence or.